The use of antimicrobial agents in COVID-19 and infections: what we know




Antibiotic; Covid; Infection.


Today, COVID-19 is causing a worrisome public health emergency and mortality is rising rapidly around the world. At the current time of the pandemic, although there has been much persistence in diagnosing several patients with symptoms or close contacts, there are no definitive guidelines for the initial therapeutic approach for them and, therefore, many patients are dying from a hyperinflammatory immune reaction labeled a "cytokine storm". The use of antimicrobials in the treatment and prevention of COVID-19, caused by the new SARS-CoV-2 coronavirus, is on the rise. Antibiotics used to treat staphylococcal infection, previously showed efficacy to inhibit the first stage of MERScoronarivus viral cycle in human cells. This activity is conserved in SARS-Cov-2, placing its use as a potential treatment for patients with this virus. A literature review using the PubMed, LILACS and Scielo databases was performed, with the terms "Covid", "antibiotic, "therapy" and "microbial resistance" and equivalents in English. In this review, we discussed some important points dedicated to the management of patients with COVID-19 using antibiotics.

Author Biography

Maykon Jhuly Martins de Paiva, Faculdade de Palmas

Departamento de Farmácia


Beigelman, A. et al. Randomized trial to evaluate azithromycin's effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis. Journal of Allergy and Clinical Immunology, 135(5), 1171-8. e1, 2015.

Cascella, M., Rajnik, M., Cuomo, A., Dulebohn, S. C., & Di Napoli, R. (2020). Features, evaluation and treatment coronavirus (COVID-19). In Statpearls [internet]. StatPearls Publishing.

Cecconi, M., Evans, L., Levy, M., & Rhodes, A. (2018). Sepsis and septic shock. The Lancet, 392(10141), 75-87.

Cespedes, M. D. S., & Souza, J. C. R. P. D. (2020). Coronavirus: a clinical update of Covid-19. Revista da Associação Médica Brasileira, 66(2), 116-123.

Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y.& Yu, T. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 395(10223), 507-513.

Clancy, C. J., & Nguyen, M. H. (2020). COVID-19, superinfections and antimicrobial development: What can we expect?. Clinical Infectious Diseases.

Cox, M. J., Loman, N., Bogaert, D., & O'grady, J. (2020). Co-infections: potentially lethal and unexplored in COVID-19. The Lancet Microbe, 1(1), e11.

Fu, Y., Cheng, Y., & Wu, Y. (2020). Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. VirologicaSinica, 1-6.

Gerberding, J. L. (2020). Antibiotic resistance: the hidden threat lurking behind Covid-19. STAT, March, 23.

Halaji, M., Farahani, A., Ranjbar, R., Heiat, M., &Dehkordi, F. S. (2020). Emerging coronaviruses: first SARS, second MERS and third SARS-CoV-2: epidemiological updates of COVID-19. Le Infezioni in Medicina, 28(suppl 1), 6-17.

Hantoushzadeh, S., & Norooznezhad, A. H. (2020). Inappropriate Antibiotic Consumption as a Possible Cause of Inflammatory Storm and Septic Shock in Patients Diagnosed with Coronavirus-19 Disease (COVID-19). Archives of Medical Research.

Hsu, J. (2020). How covid-19 is accelerating the threat of antimicrobial resistance. BMJ, 369.

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y. & Cheng, Z. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet, 395(10223), 497-506.

Huttner, B., Catho, G., Pano-Pardo, J. R., Pulcini, C., & Schouten, J. (2020). COVID-19: don’t neglect antimicrobial stewardship principles!. Clinical Microbiology and Infection.

Jin, Y. H., Cai, L., Cheng, Z. S., Cheng, H., Deng, T., Fan, Y. P.,& Han, Y. (2019). for the Zhongnan Hospital of Wuhan University Novel Coronavirus Management and Research Team. Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM). A rapid advice guideline for the diagnosis and treatment of.

Klein, E. Y., Monteforte, B., Gupta, A., Jiang, W., May, L., Hsieh, Y. H., &Dugas, A. (2016). The frequency of influenza and bacterial coinfection: a systematic review and meta‐analysis. Influenza and other respiratory viruses, 10(5), 394-403.

Lai, CC, Wang, CY e Hsueh, PR (2020). Coinfecções entre pacientes com COVID-19: A necessidade de terapia combinada com agentes não anti-SARS-CoV-2 ?. Journal of Microbiology, Immunology and Infection .

Lansbury, L., Lim, B., Baskaran, V., & Lim, W. S. (2020). Co-infections in people with COVID-19: a systematic review and meta-analysis. Journal of Infection.

Lupia, T., Scabini, S., Pinna, S. M., Di Perri, G., De Rosa, F. G., &Corcione, S. (2020). 2019-novel coronavirus outbreak: A new challenge. Journal of Global Antimicrobial Resistance.

Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., Manson, J. J., & HLH Across Speciality Collaboration. (2020). COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England), 395(10229), 1033.

Meier, M. A., Branche, A., Neeser, O. L., Wirz, Y., Haubitz, S., Bouadma, L.,& Christ-Crain, M. (2019). Procalcitonin-guided antibiotic treatment in patients with positive blood cultures: a patient-level meta-analysis of randomized trials. Clinical Infectious Diseases, 69(3), 388-396.

Min, J. Y., & Jang, Y. J. (2012). Macrolide therapy in respiratory viral infections. Mediators of inflammation, 2012.

Mohammadpour, S., TorshiziEsfahani, A., Halaji, M., Lak, M., &Ranjbar, R. (2020). Uma revisão atualizada da associação de fatores genéticos do hospedeiro com susceptibilidade e resistência ao COVID ‐ 19. Journal of Cellular Physiology .

Pani, A., Lauriola, M., Romandini, A., & Scaglione, F. (2020). Macrolídeos e infecções virais: enfoque na azitromicina na patologia de COVID-19. International Journal of Antimicrobial Agents , 106053.

PEREIRA, A. S. et al. (2018). Metodologia da pesquisa científica. Santa Maria: UAB/NTE/UFSM.

Perlman, S., & Netland, J. (2009). Coronavírus pós-SARS: atualização sobre replicação e patogênese. Nature reviews microbiology, 7(6), 439-450.

Phelan, A. L., Katz, R., &Gostin, L. O. (2020). The novel coronavirus originating in Wuhan, China: challenges for global health governance. Jama, 323(8), 709-710.

Rawson, T. M., Moore, L. S., Zhu, N., Ranganathan, N., Skolimowska, K., Gilchrist, M.,& Holmes, A. (2020). Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. Clinical Infectious Diseases

Rodriguez-Morales, A. J., Cardona-Ospina, J. A., Gutiérrez-Ocampo, E., Villamizar-Peña, R., Holguin-Rivera, Y., Escalera-Antezana, J. P.&Paniz-Mondolfi, A. (2020). Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel medicine and infectious disease, 101623.

Rothan, H. A., &Byrareddy, S. N. (2020). The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of autoimmunity, 102433.

Sodhi, M., & Etminan, M. (2020). Therapeutic Potential for Tetracyclines in the Treatment of COVID‐19. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 40(5), 487-88.

Spernovasilis, N., & Kofteridis, D. (2020). COVID-19 and antimicrobial stewardship: What is the interplay? Infection Control & Hospital Epidemiology, 1-6.

Stevens, M. P., Patel, P. K., &Nori, P. (2020). Involving antimicrobial stewardship programs in COVID-19 response efforts: all hands on deck. Infection Control & Hospital Epidemiology, 41(6), 744-745.

Thompson III, G. R., Cornely, O. A., Pappas, P. G., Patterson, T. F., Hoenigl, M., Jenks, J. D., ... & Nguyen, M. H. (2020, July). Invasive Aspergillosis as an Under-recognized Superinfection in COVID-19. In Open Forum Infectious Diseases. 7(7), p. ofaa242). US: Oxford University Press.

Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., & Zhao, Y. (2020). Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama, 323(11), 1061-1069.

Wei, W., Ortwine, J. K., Mang, N. S., Joseph, C., Hall, B. C., & Prokesch, B. C. (2020). Limited Role for Antibiotics in COVID-19: Scarce Evidence of Bacterial Coinfection. Available at SSRN 3622388.

WORLD HEALTH ORGANIZATION et al. Coronavirus disease 2019 (COVID-19): situation report, 72. 2020.

Zhang, J., Ma, X., Yu, F., Liu, J., Zou, F., Pan, T., & Zhang, H. (2020). Teicoplanin potently blocks the cell entry of 2019-nCoV. BioRxiv.

Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z.,& Guan, L. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet.

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J.&Niu, P. (2020). A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine.

Yap, F. H., Gomersall, C. D., Fung, K. S., Ho, P. L., Ho, O. M., Lam, P. K.& Joynt, G. M. (2004). Increase in methicillin-resistant Staphylococcus aureus acquisition rate and change in pathogen pattern associated with an outbreak of severe acute respiratory syndrome. Clinical infectious diseases, 39(4), 511-516.

Ye, Q., Wang, B., & Mao, J. (2020). The pathogenesis and treatment of theCytokineStorm'in COVID-19. Journal of infection, 80(6), 607-13.



How to Cite

Vellano, P. O. ., & Paiva, M. J. M. de. (2020). The use of antimicrobial agents in COVID-19 and infections: what we know. Research, Society and Development, 9(9), e841997245.



Health Sciences